|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | |  |  | **MD Anderson Cohort** | | | **Georgetown Cohort** | | | |  |  | **Lung cancer** | **AD** | **SCC** | **Lung cancer** | **AD** | **SCC** | | **All patients** | 5-yr survival  rate for NSAID users | 29.7% | 27.1% | 31.3% | 40.5% | 40.5% | 40.7% | |  | 5-yr survival  rate for NSAID non-users | 13.1% | 12.9% | 14.4% | 26.5% | 29.2% | 23.0% | |  | difference in 5-year RMST  (months) | 11.6 | 10.9 | 11.0 | 8.6 | 6.7 | 10.4 | | **Stage I** | 5-yr survival  rate for NSAID users | 70.7% | 68.7% | 63.3% | 67.2% | 67.8% | 58.8% | |  | 5-yr survival  rate for NSAID non-users | 58.0% | 61.4% | 47.3% | 53.8% | 57.5% | 42.8% | |  | difference in 5-year RMST  (months) | 5.9 | 3.9 | 6.6 | 5.5 | 3.3 | 7.4 | | **Stage II** | 5-yr survival  rate for NSAID users | 49.9% | 45.2% | 52.6% | 46.9% | 53.9% | 43.6% | |  | 5-yr survival  rate for NSAID non-users | 38.0% | 43.8% | 31.3% | 34.4 % | 38.8% | 35.7% | |  | difference in 5-year RMST  (months) | 7.1 | 5.0 | 8.3 | 3.5 | 1.0 | 4.9 | | **Stage III** | 5-yr survival  rate for NSAID users | 30.5% | 29.8% | 29.0% | 30.1% | 27.0% | 36.9% | |  | 5-yr survival  rate for NSAID non-users | 17.5% | 19.4% | 15.4% | 19.9% | 28.1% | 11.0% | |  | difference in 5-year RMST  (months) | 9.3 | 9.1 | 7.7 | 7.3 | 0.6 | 16.1 | | **Stage IV** | 5-yr survival  rate for NSAID users | 7.2% | 10.1% | 2.0% | 13.4% | 13.1% | 11.2% | |  | 5-yr survival  rate for NSAID non-users | 4.2% | 5.2% | 2.6% | 11.4% | 13.7% | 9.2% | |  | difference in 5-year RMST  (months) | 3.6 | 4.1 | 1.1 | 3.8 | 3.1 | 2.0 |   **Supplementary Table 5:** The MD Anderson and Georgetown cohorts 5-year survival rates and differences of 5-year restricted mean survival time in months between NSAID users and non-users for all patients and by stage and histopathology corresponding to **Figure 1.** The abbreviations are AD (adenocarcinoma) and SCC (squamous cell cancer), respectively. |